LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) Stock Income Statement
NASDAQ:LIXT - Nasdaq - US5393193017 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 3.57M | 5.09M | 6.31M | 6.72M | 3.27M | |||
| Research and Development | 726.20K | 898.10K | 1.35M | 1.74M | 1.22M | |||
| Selling, General, and Administrative Expenses | 2.85M | 2.70M | 4.96M | 4.98M | 2.04M | |||
| Operating Income | -3.57M | -5.09M | -6.31M | -6.72M | -3.27M | |||
| Interest Income/Expense | -13.20K | 3.20K | 0.00 | -10.00K | 0.00 | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | N/A | |||
| Income Before Taxes | -3.59M | -5.09M | -6.31M | -6.73M | -3.26M | |||
| Net Income | -3.59M | -5.09M | -6.31M | -6.73M | -3.26M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.59 | -2.66 | -3.99 | -4.99 | -2.90 | |||
| Statistics | ||||||||
| Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
| Operating Profit Margin | N/A | N/A | N/A | N/A | N/A | |||
All data in USD